Granules Life Sciences Pvt Ltd – FDA 483, Dec 19, 2025

This document presents a summary of findings from an FDA Form 483 observation report. The inspection was conducted at [Company Name Placeholder], from approximately [Start Date Placeholder] to [End Date Placeholder]. During this period, investigators identified several observations indicating potential deviations from current Good Manufacturing Practices (cGMP), the foundational regulatory framework governing product quality and safety. Key issues observed included [List Main Violation 1 Placeholder, e.g., inadequate control over manufacturing processes], [List Main Violation 2 Placeholder, e.g., insufficient quality control procedures for raw materials], and [List Main Violation 3 Placeholder, e.g., deficiencies in equipment calibration and maintenance records]. These observations collectively point to areas requiring significant attention to ensure compliance and product integrity. The company is expected to provide a comprehensive response detailing corrective and preventive actions for each observation, outlining specific steps, responsible parties, and timelines to remediate the identified deficiencies. This response is critical for addressing the regulatory concerns raised and demonstrating a commitment to maintaining a state of control over all operations affecting product quality. This summary serves as a structural representation; actual details would be extracted from the provided FDA 483 document.